Loading
A phase 3 trial of Cetuximab in colorectal cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) is a phase 3 interventional study registered as NCT04793958 by Mirati Therapeutics Inc., with 461 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2026-01-16. Interventions recorded: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen. Conditions listed: Advanced Colorectal Cancer, Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CodeBreaK 300, KRAS G12C-mutant colorectal cancer, Monoclonal antibodies, Colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares Cetuximab, Monoclonal antibodies.
Shares Cetuximab, Bristol Myers Squibb, Colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies.
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/